GlobalData on MSN1d
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
FiercePharma2d
Johnson & Johnson eases initial Stelara blows with strong Darzalex, Carvykti growth
Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...
What's Next For Johnson & Johnson Stock?
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
BioSpace2d
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on ...
FiercePharma3d
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
Pharmaceutical Technology on MSN5d
South Korean company Dong-A ST wins FDA approval for Stelara biosimilar
Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
Managed Healthcare Executive2d
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
The American Journal of Managed Care5d
FDA Approves Imuldosa, a Fifth Biosimilar to Stelara
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Drug Store News2d
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...
Monthly Prescribing Reference1d
FDA Approves Stelara Biosimilar Imuldosa
The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...